Literature DB >> 26761923

Phenotype HNPP (Hereditary Neuropathy With Liability to Pressure Palsies) Induced by Medical Procedures.

Mark Kramer1, Amy Ly, Jun Li.   

Abstract

The phenotype HNPP (hereditary neuropathy with liability to pressure palsies) is caused by heterozygous deletion of the PMP22 gene. HNPP is clinically characterized by asymmetric focal sensory loss and muscle weakness. Reports of HNPP have been rare. In this article, we report the case of an asymptomatic woman with the HNPP mutation. After undergoing total knee arthroplasty, she developed a footdrop with prolonged recovery. We concluded (a) that the HNPP mutation may carry a high risk for certain surgical procedures not expected to cause neurologic deficits in normal patients and (b) that humans with the HNPP mutation can be asymptomatic. Lack of symptoms can contribute to underrecognition of the disease.

Entities:  

Mesh:

Year:  2016        PMID: 26761923      PMCID: PMC4876709     

Source DB:  PubMed          Journal:  Am J Orthop (Belle Mead NJ)        ISSN: 1078-4519


  11 in total

Review 1.  Peroneal nerve palsy after total knee arthroplasty.

Authors:  Ohannes A Nercessian; Obinwanne F C Ugwonali; Sangdo Park
Journal:  J Arthroplasty       Date:  2005-12       Impact factor: 4.757

2.  Epidemiology of hereditary neuropathy with liability to pressure palsies (HNPP) in south western Finland.

Authors:  P Meretoja; K Silander; H Kalimo; P Aula; A Meretoja; M L Savontaus
Journal:  Neuromuscul Disord       Date:  1997-12       Impact factor: 4.296

3.  Abnormal junctions and permeability of myelin in PMP22-deficient nerves.

Authors:  Jiasong Guo; Leiming Wang; Yang Zhang; Jiawen Wu; Sezgi Arpag; Bo Hu; Beat A Imhof; Xinxia Tian; Bruce D Carter; Ueli Suter; Jun Li
Journal:  Ann Neurol       Date:  2014-02-20       Impact factor: 10.422

4.  Nerve injury after primary total knee arthroplasty.

Authors:  M F Schinsky; W Macaulay; M L Parks; H Kiernan; O A Nercessian
Journal:  J Arthroplasty       Date:  2001-12       Impact factor: 4.757

5.  DNA duplication associated with Charcot-Marie-Tooth disease type 1A.

Authors:  J R Lupski; R M de Oca-Luna; S Slaugenhaupt; L Pentao; V Guzzetta; B J Trask; O Saucedo-Cardenas; D F Barker; J M Killian; C A Garcia; A Chakravarti; P I Patel
Journal:  Cell       Date:  1991-07-26       Impact factor: 41.582

6.  Estimation of the size of the chromosome 17p11.2 duplication in Charcot-Marie-Tooth neuropathy type 1a (CMT1a). HMSN Collaborative Research Group.

Authors:  P Raeymaekers; V Timmerman; E Nelis; W Van Hul; P De Jonghe; J J Martin; C Van Broeckhoven
Journal:  J Med Genet       Date:  1992-01       Impact factor: 6.318

Review 7.  The PMP22 gene and its related diseases.

Authors:  Jun Li; Brett Parker; Colin Martyn; Chandramohan Natarajan; Jiasong Guo
Journal:  Mol Neurobiol       Date:  2012-12-07       Impact factor: 5.590

8.  Peroneal-nerve palsy following total knee arthroplasty. A review of The Hospital for Special Surgery experience.

Authors:  H A Rose; R W Hood; J C Otis; C S Ranawat; J N Insall
Journal:  J Bone Joint Surg Am       Date:  1982-03       Impact factor: 5.284

9.  Conduction block in PMP22 deficiency.

Authors:  Yunhong Bai; Xuebao Zhang; Istvan Katona; Mario Andre Saporta; Michael E Shy; Heather A O'Malley; Lori L Isom; Ueli Suter; Jun Li
Journal:  J Neurosci       Date:  2010-01-13       Impact factor: 6.167

10.  Hereditary neuropathy with liability to pressure palsy: the electrophysiology fits the name.

Authors:  Jun Li; Karen Krajewski; Michael E Shy; Richard A Lewis
Journal:  Neurology       Date:  2002-06-25       Impact factor: 9.910

View more
  2 in total

Review 1.  Hereditary neuropathy with liability to pressure palsies.

Authors:  Shahram Attarian; Farzad Fatehi; Yusuf A Rajabally; Davide Pareyson
Journal:  J Neurol       Date:  2019-04-15       Impact factor: 4.849

Review 2.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.